title: Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
abstract: To evaluate the use of pretargeted immunoscintigraphy (ISG) in the diagnosis and follow-up of patients with medullary thyroid carcinoma (MTC), we studied 25 patients with histologically proven disease; ISG was repeated after surgery in two patients. The antibody, either an anticarcinoembryonic antigen (CEA) or an antichromogranin A (CgA) biotinylated monoclonal antibody (MAb) or a cocktail of the two biotinylated MAbs was first injected. After 24 h, avidin was administrated i.v., followed by 111In-labelled biotin 24 h later. Fifty-two lesions were visualised. Six primary tumours, diagnosed by increased calcitonin levels, were all correctly diagnosed; 47 recurrences, also suspected by blood tumour markers, were detected and confirmed by cytology or histology. In one case, single photon emission tomography allowed the detection of small lymph nodes with a diameter of 4-7 mm. These lesions, not judged neoplastic by ultrasound, were confirmed to be neoplastic by fine needle aspiration. Pretargeted ISG correctly localises primary tumours and recurrences in MTC patients, when the only marker of relapse is serum elevation of calcitonin. With this three-step pretargeting method, cocktails of potentially useful MAbs can be used, avoiding false-negative studies that may occur when CEA or CgA are not expressed.
authors.affiliation: Institute H San Raffaele, University of Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Magnani
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
authors.forename: C
authors.initials: C
authors.lastname: Songini
authors.forename: A
authors.initials: A
authors.lastname: Samuel
authors.forename: F
authors.initials: F
authors.lastname: Sudati
authors.forename: A G
authors.initials: AG
authors.lastname: Siccardi
authors.forename: F
authors.initials: F
authors.lastname: Fazio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001360:Avidin / Q000009:adverse effects / Q000276:immunology; D001710:Biotin; D002272:Carcinoembryonic Antigen; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000556:secondary; D053379:Chromogranin A; D002864:Chromogranins / Q000276:immunology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D011237:Predictive Value of Tests; D016719:Radioimmunodetection; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D053379:Chromogranin A; D002864:Chromogranins; D001360:Avidin; D001710:Biotin